Tag: press release

OSLO, Norway (8 August 2025) – TGS, a leading provider of energy data and intelligence, is pleased to announce the award of a streamer acquisition contract in the East Mediterranean. Acquisition is scheduled to commence in Q3 this year and the contract has a duration of approximately 30 days.

AVTL to develop new terminal in JNPA, India


Rotterdam, the Netherlands, 8 August 2025

In India, AVTL announced a positive final investment decision to build a greenfield terminal for 132k cbm LPG and 318k cbm liquid products and a LPG bottling plant of 35,000MT capacity in the JNPA port in Mumbai. This is AVTL's second terminal in the JNPA port which will help grow its market share in servicing a highly industrialized and fast growing hinterland of West and central regions in India. The terminal is expected to be commissioned in phases starting mid 2026.

The full investment amount of EUR 170 million, of which the Vopak share is EUR 70 million, will be funded by AVTL. AVTL has recently completed an IPO (link IPO press release).

Vopak is a 42.23% shareholder in AVTL. Vopak's global growth strategy includes industrial and gas infrastructure and infrastructure needed for the energy transition. 

About AVTL
AVTL, a publicly listed company, is the largest Indian third-party owner and operator of tank storage terminals for liquified petroleum gas and liquid products in terms of storage capacity. AVTL, along with its subsidiaries, owns and operates a network of storage tank terminals (LPG and chemicals) across six Indian ports.


About Royal Vopak
Royal Vopak helps the world flow forward. At ports around the world, we provide storage and infrastructure solutions for vital products that enrich everyday life. These products include liquids and gases that provide energy for homes and businesses, chemicals for manufacturing products, and edible oils for cooking. For all of these, our worldwide network of terminals supports the global flow of supply and demand. For more than 400 years, Royal Vopak has been at the forefront of fundamental transformations. With a focus on safety, reliability, and efficiency, we create new connections and opportunities that drive progress. Now more than ever, our talented people are applying this mindset to support the energy transition. Together with our partners and customers, we are accelerating the development of infrastructure solutions for hydrogen, ammonia, CO₂, battery energy storage systems, and low-carbon fuels & feedstocks – paving the way to a more sustainable future. Vopak is listed on the Euronext Amsterdam and is headquartered in Rotterdam, the Netherlands. For more information, please visit www.vopak.com.


For more information please contact:
Vopak Press: Liesbeth Lans - Manager External Communication - global.communication@vopak.com 
Vopak Analysts and Investors: Fatjona Topciu - Head of Investor Relations- investor.relations@vopak.com

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.

CALGARY, Alberta, Aug. 07, 2025 (GLOBE NEWSWIRE) -- FLINT Corp. ("FLINT" or the "Company") (TSX: FLNT) is pleased to announce a proposed recapitalization transaction (the "Recapitalization") that will significantly reduce the Company's debt and annual interest costs, simplify its capital structure and improve liquidity. The Recapitalization is the result of an extensive review process conducted by the Company's board of directors (the "Board"), which culminated in FLINT entering into a definitive recapitalization support agreement (the "Support Agreement") with its largest shareholder and primary lender, Canso Investment Counsel Ltd., in its capacity as portfolio manager for and on behalf of certain accounts that it manages ("Canso"). The Recapitalization is intended to preserve value for the Company's shareholders and better position FLINT to execute on future growth opportunities.

CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of its underwritten public offering of 6,000,000 units, with each unit consisting of one share of common stock and one warrant (the “Warrants”) (or pre-funded units in lieu thereof, with each pre-funded unit consisting of one pre-funded warrant (the “Pre-Funded Warrants”) and one Warrant). Each unit is being sold to the public at a price of $2.00 per unit (and each pre-funded unit is being sold to the public at the public offering price of each unit less the $0.0001 per share nominal exercise price for each Pre-Funded Warrant). The gross proceeds to the Company from this offering are expected to be approximately $12 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Warrants included in the units and pre-funded units have been approved for listing on the Nasdaq Capital Market and are expected to commence trading under the symbol “BIVIW” on August 8, 2025. Each Warrant will be immediately exercisable, will entitle the holder to purchase one share of common stock at an exercise price of $2.50 per share and will expire five years from the date of issuance. Each Pre-Funded Warrant will be immediately exercisable, will entitle the holder to purchase one share of common stock and may be exercised at any time until exercised in full. The common stock (or Pre-Funded Warrants in lieu thereof) and Warrants can only be purchased together in the offering but will be issued separately. The Company has granted the underwriter a 45-day option to purchase up to an additional 900,000 shares of common stock and/or Pre-Funded Warrants and/or Warrants, or any combination thereof, solely to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions.

MOUNTAIN VIEW, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the pricing of its upsized initial public offering of 16,666,667 shares of its common stock at a public offering price of $19.00 per share. All of the shares of common stock are being offered by Heartflow. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Heartflow, are expected to be approximately $316.7 million. In addition, Heartflow has granted the underwriters a 30-day option to purchase up to an additional 2,500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on August 8, 2025 under the ticker symbol "HTFL.” The closing of the offering is expected to occur on August 11, 2025, subject to the satisfaction of customary closing conditions.

HONG KONG, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Etoiles Capital Group Co., Ltd (Nasdaq: EFTY), a Hong Kong-headquartered financial services firm, today priced its initial public offering (the “Offering”) of 1,400,000 Class A ordinary shares at $4.00 per share. The Class A ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on August 8, 2025 under the ticker symbol “EFTY.”

ACTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced financial results for the quarter ended June 30, 2025, and provided an update on its Symphony IL-6 test program and key operational milestones.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Quarter Sales of $191.9 million, up 74% from a year earlier,